“Given the robust efficacy and safety results observed in our recently completed Alzheimer’s disease clinical study of Dimebon, we are excited about Dimebon’s potential to benefit Huntington’s disease patients,” said David Hung, CEO of Medivation.
Medivation is conducting the Huntington’s disease trial in collaboration with the Huntington Study Group. The study will be conducted at approximately 12 Huntington Study Group sites in the US.
The Huntington’s disease clinical trial has two parts: a dose-escalation phase to determine the optimal doses of Dimebon, followed by phase to evaluate the safety and preliminary efficacy of those doses in Huntington’s disease patients.
The FDA has requested toxicology studies before the second part of the study can begin. Results are expected in the second half of 2007.